Education
About Us
Working with TipRanks
Follow Us
Lifeward (LFWD)
NASDAQ:LFWD
Top Page
Lifeward
(NASDAQ:LFWD)
Select Model
Select Model
Rating:43Neutral
Price Target:―
Lifeward's stock score is influenced by strong revenue growth but substantial risks due to profitability challenges, negative cash flows, and unattractive valuation. Technical indicators and recent corporate events further underscore the cautious outlook, despite strategic initiatives. Key risks involve financial instability and operational inefficiencies.
Positive Factors
Revenue Growth
Strong revenue growth indicates increasing market demand and successful product adoption, which can drive long-term business expansion and stability.
Strategic Partnerships
Strategic partnerships and market expansion efforts enhance Lifeward's competitive position and open new revenue streams, supporting sustainable growth.
New Product Launches
New product launches and regulatory approvals can drive future sales growth and strengthen market position, enhancing long-term competitiveness.
Negative Factors
Profitability Challenges
Persistent profitability challenges highlight operational inefficiencies, which can hinder financial sustainability and limit growth potential.
Negative Cash Flow
Negative cash flow suggests operational cash deficits, increasing reliance on external funding, which can strain financial health and limit strategic flexibility.
Leadership Changes
Leadership changes can disrupt strategic direction and sales execution, potentially impacting operational stability and long-term growth strategies.
Lifeward (LFWD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.54M
Dividend YieldN/A
Average Volume (3M)376.71K
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue Growth4.96%
EPS Growth-13.09%
CountryUS
Employees80
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.31
Shares Outstanding15,704,622
10 Day Avg. Volume539,603
30 Day Avg. Volume376,706
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.18
Enterprise Value/Revenue0.09
Enterprise Value/Gross Profit0.26
Enterprise Value/Ebitda-0.14
Forecast
1Y Price Target
$3.00Price Target Upside270.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Lifeward Business Overview & Revenue Model
Company Descriptionnull
How the Company Makes Moneynull
Lifeward Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 18, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with significant achievements in product placements and operational efficiencies, particularly in Germany, counterbalanced by revenue decline and a substantial goodwill impairment charge. The company is optimistic about future growth but has adjusted its guidance to reflect current challenges.Q2-2025 Updates
Positive Updates
Record Quarter for ReWalk Medicare Placements
Revenue for Q2 2025 was $5.7 million, reflecting a record quarter for ReWalk Medicare placements.
Transition to In-House Manufacturing
Completed the transition to in-house manufacturing of the ReWalk Personal Exoskeleton, delivering cost savings, improved quality control, and greater production flexibility.
Growth in Active Pipeline
The active pipeline in the U.S. grew by 86% since Q3 2024, with more than 130 qualified leads in process.
Operational Efficiencies
Improved quarterly cash burn to $3.9 million, down from $5.6 million in Q2 2024, driven by operational efficiencies and facility consolidations.
International Success in Germany
The GmbH team in Germany is operating profitably, building a strong patient community, and using their payer acceleration and market scale to move quickly in rolling out innovative new business models.
Negative Updates
Revenue Decline Year-Over-Year
Year-over-year, Lifeward reported revenues of $5.7 million in Q2 2025 compared to $6.7 million in the second quarter of 2024, a decrease of $1 million or about 15%.
Goodwill Impairment Charge
A $2.8 million goodwill impairment charge was triggered by a significant decline in share price, creating a gap between market value and book value.
Inventory and Cash Flow Challenges
Inventory increased due to the transition to in-house manufacturing and supporting production for both the ReWalk 6 and ReWalk 7, impacting cash flow.
Guidance Adjustment
Lifeward reset its full 2025 guidance under the new management team, with projected non-GAAP net loss in the range of $12 million to $14 million.
Company Guidance
In the second quarter of 2025, Lifeward reported revenue of $5.7 million, marking a 14% increase from the previous quarter but a 15% decrease from the same period in 2024. The company achieved a record quarter for ReWalk Medicare placements, with over 20 ReWalk 7 units installed in the U.S. and positive feedback from users. Operational improvements led to a reduced cash burn of $3.9 million, down from $5.6 million in Q2 2024. Lifeward's strategic focus involves three pillars: accelerating commercial adoption, diversifying its product portfolio, and enhancing operational excellence. The company's guidance for 2025 forecasts full-year revenue between $24 million and $26 million, with a non-GAAP net loss of $12 million to $14 million. The company is working on expanding its payer base and expects further growth in ReWalk revenues in the latter half of the year.Lifeward Financial Statement Overview
Summary
Lifeward is experiencing strong revenue growth but faces significant profitability challenges. The company has a healthy balance sheet with a high equity ratio, though negative cash flows and earnings pose risks. Future improvements in operational efficiency are crucial for financial sustainability.Income Statement
Lifeward's revenue has shown strong growth, from $4.4 million in 2020 to $25.7 million in 2024, marking a significant upward trajectory. However, the company has consistently posted negative EBIT and net income, indicating operational inefficiencies and challenges in achieving profitability. The gross profit margin is improving but remains offset by high operating expenses.35
Negative
Balance Sheet
The company has a healthy stockholders' equity position, which is significantly higher than its total liabilities, resulting in a low debt-to-equity ratio. However, the return on equity is negative due to consistent net losses, highlighting a risk of financial instability despite the strong equity base.45
Neutral
Cash Flow
Lifeward experiences negative operating and free cash flow, indicating reliance on external financing for operations. The free cash flow growth rate is negative, showing challenges in converting revenue to cash. Cash flow ratios to net income are unfavorable, reflecting operational cash deficits.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.43M | 25.66M | 13.85M | 5.51M | 5.97M | 4.39M |
| Gross Profit | 8.70M | 8.22M | 4.45M | 1.91M | 2.90M | 2.19M |
| EBITDA | -16.19M | -24.93M | -21.77M | -18.90M | -12.39M | -11.73M |
| Net Income | -29.76M | -28.94M | -22.13M | -19.57M | -12.74M | -12.98M |
Balance Sheet | ||||||
| Total Assets | 26.78M | 30.49M | 63.19M | 74.24M | 94.75M | 28.07M |
| Cash, Cash Equivalents and Short-Term Investments | 5.14M | 6.75M | 28.08M | 67.90M | 88.34M | 20.35M |
| Total Debt | 375.00K | 880.00K | 1.90M | 897.00K | 1.06M | 1.58M |
| Total Liabilities | 11.67M | 11.64M | 16.68M | 6.07M | 5.37M | 6.29M |
| Stockholders Equity | 15.11M | 18.85M | 46.51M | 68.17M | 89.38M | 21.77M |
Cash Flow | ||||||
| Free Cash Flow | -17.86M | -21.72M | -20.75M | -17.92M | -11.52M | -12.66M |
| Operating Cash Flow | -17.86M | -21.72M | -20.67M | -17.89M | -11.47M | -12.59M |
| Investing Cash Flow | 18.14M | 0.00 | -18.15M | -25.00K | -47.00K | -73.00K |
| Financing Cash Flow | 2.07M | 0.00 | -992.00K | -2.50M | 79.51M | 16.72M |
Lifeward Technical Analysis
Positive
0.81
Price Trends
0.66
Positive
0.80
Positive
1.21
Negative
Market Momentum
0.05
Negative
66.05
Neutral
74.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFWD, the sentiment is Positive. The current price of 0.81 is above the 20-day moving average (MA) of 0.70, above the 50-day MA of 0.66, and below the 200-day MA of 1.21, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 66.05 is Neutral, neither overbought nor oversold. The STOCH value of 74.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFWD.
Lifeward Risk Analysis
Lifeward disclosed 62 risk factors in its most recent earnings report. Lifeward reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
Lifeward Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $10.26M | 0.42 | -499.57% | ― | -73.36% | ― | |
45 Neutral | $18.04M | ― | -63.40% | ― | -91.14% | 9.47% | |
43 Neutral | $12.54M | ― | -114.90% | ― | 4.96% | -13.09% | |
41 Neutral | $10.40M | ― | 9.26% | ― | ― | ― | |
40 Underperform | $19.36M | ― | -323.27% | ― | 168.20% | 63.41% | |
40 Underperform | $8.15M | ― | -92.99% | ― | -1.88% | 23.99% |
* Healthcare Sector Average
LFWD
Lifeward
0.81
-2.06
-71.78%
BMRA
Biomerica
2.95
0.34
13.03%
CODX
Co-Diagnostics
0.43
-0.85
-66.41%
XAIR
Beyond Air
2.69
-4.13
-60.56%
PAVM
PAVmed
0.49
-0.67
-57.76%
DHAI
DIH Holdings US, Inc Class A
0.20
-1.48
-88.10%
Lifeward Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Lifeward Announces Termination of Chief Sales Officer
Negative
Apr 14, 2025
Lifeward has announced that Charles Remsberg’s role as Chief Sales Officer will be terminated without cause, effective May 30, 2025. This decision, disclosed in the company’s annual report, ensures Mr. Remsberg will receive severance and benefits as per his employment agreement, potentially impacting the company’s sales leadership and strategy.
Spark’s Take on LFWD Stock
According to Spark, TipRanks’ AI Analyst, LFWD is a Neutral.
Lifeward’s stock is rated low primarily due to ongoing financial challenges, despite strong revenue growth. Technical indicators suggest a current downtrend, and valuation metrics are unattractive due to negative earnings. While strategic initiatives show promise, the high risks associated with financial instability and operational inefficiencies are significant concerns.
To see Spark’s full report on LFWD stock, click here.
Executive/Board Changes
Rewalk Robotics CEO Larry Jasinski to Step Down
Neutral
Feb 20, 2025
On February 19, 2025, Rewalk Robotics announced that Larry Jasinski will step down as CEO and board member by the end of the second quarter of 2025. Jasinski’s departure will be considered a termination without cause, and the company plans to finalize a separation agreement with him before his exit.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.